Karyopharm to Participate in Baird's Biotech Discovery Series
Rhea-AI Summary
Karyopharm (Nasdaq: KPTI) announced that its senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET.
Dr. Harrison is Professor of Myeloproliferative Neoplasms and Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and is described as a leading international expert in myelofibrosis. A live webcast will be available under the company's Investor "Events & Presentations" page and will be posted for replay after the event.
Positive
- None.
Negative
- None.
News Market Reaction – KPTI
In the Dec 8 session, KPTI gained 2.43%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.2% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Inducement grants | Neutral | -6.8% | Inducement stock options and RSUs granted to new hires under 2022 plan. |
| Dec 01 | Conference participation | Neutral | +2.3% | Management fireside chat at Piper Sandler healthcare conference with webcast replay. |
| Nov 03 | Inducement RSU grant | Neutral | +4.7% | Single-employee RSU inducement grant under Nasdaq Listing Rule 5635(c)(4). |
| Nov 03 | Earnings and pipeline | Neutral | +4.7% | Q3 2025 results and progress, including SENTRY Phase 3 myelofibrosis enrollment. |
| Oct 27 | Earnings date notice | Neutral | +1.3% | Announcement of Q3 2025 results date and related conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Over the last few months, Karyopharm has reported Q3 2025 results with $44.0M revenue and highlighted completion of enrollment in the Phase 3 SENTRY myelofibrosis trial. The company also issued multiple inducement RSU and option grants and participated in investor conferences, with share-price reactions ranging from about -6.78% to +4.66%. Today’s Baird Biotech Discovery Series fireside chat fits into this pattern of ongoing investor-relations outreach rather than a discrete clinical or financial catalyst.
Key Terms
myeloproliferative neoplasms medical
myelofibrosis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the event can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-in-bairds-biotech-discovery-series-302634110.html
SOURCE Karyopharm Therapeutics Inc.